RED: NICE TA220: psoriatic arthritis (decision date - May 2011)
RED: NICE TA 225: rheumaoid athritis - a recommended option (in the same circumstances as TA130) after other specified treatments have failed or not been tolerated (decision date - July 2011)
RED: NICE TA233: a recommended option for severe, active ankylosing spondylitis in the same circumstances as TA143 when NSAIDs unsuccessful (decision date - Sept 2011)
RED: NICE TA329: recommended option for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (decision date - March 2015)
RED:1,2,3 NICE TA375 for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (this TA partially replaces TA225) (decision date - Feb 2016)
RED1,2,3: NICE TA383 for ankylosing spondylitis and non-radiographic axial spondyloarthritis (decision date - March 2016)
RED1,2,3: NICE TA497 for treating non-radiographic axial spondyloarthritis (Decision date - February 2018)
CCG commissioned drug.